Incyte tries to fend off TRC's mini-tender offer to investors; Gritstone Oncology scoops Actelion CFO Jean-Marc Bellemin
→ Incyte $INCY is counting on its investors to protect 0.71% — or 1,500,000 shares — of its common stock, from Canada’s TRC Capital, which is out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
